In a more recent study of acquired MET inhibitor resistance in GBM, Cruickshanks et al. found compensatory upregulation of a number of other signaling pathways, including MAPK, PI3K, and STAT [152]. The gene discussed is SOAT1; the disease is glioblastoma.